1-methyl-3-isobutylxanthine has been researched along with Bright Disease in 1 studies
1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES
3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Valentin, JP | 1 |
| Ying, WZ | 1 |
| Sechi, LA | 1 |
| Ling, KT | 1 |
| Qiu, C | 1 |
| Couser, WG | 1 |
| Humphreys, MH | 1 |
1 other study available for 1-methyl-3-isobutylxanthine and Bright Disease
| Article | Year |
|---|---|
Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann Nephritis.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Atrial Natriuretic Factor | 1996 |